Redeye comments on Dynavox’s Q2 report released earlier this morning.
Atria reported Q2 adjusted EBIT of EUR 20.7m, 15% above LSEG Data & Analytics consensus.
Redeye updates on Hacksaw after Q2-results which were close to our forecasts, albeit with slightly l...
Physitrack's Q2 marked a return to growth — revenue up 8% and ARR of EUR 13.
* Net sales -6% y-o-y, EBITA -13% y-o-y * Strategic staffing-up now in comps, DTC progressing well *...
Ahead of Siili’s Q2 report, we make another round of estimate cuts.
* Earnings improved materially y-o-y, but less than we estimated * We cut EBITA estimates by EUR 3m ...
* OEM ramping up, encouraging aftermarket * '26e-'27e EBIT down 3%; ~55% EBIT CAGR '25-'28e * 21-11x...
Redeye updates its estimates and valuation after VEF’s Q2 2026 report.
* Better organic growth (-4% vs. ABG -10%) * Next phase of OEM ramp-up Q1'27, AM back to y-o-y growt...
Physitrack's Q2 2026 report came in slightly ahead of our expectations.
Seafire has now reported seven consecutive quarters of organic earnings growth, which we find impres...
Redeye shares its initial take on Modelon's Q2 2026 report.
Redeye comments on Hacksaw’s Q2-results which were close to our forecasts as the company continued t...
Redeye updates on Invisio after Q2-results which saw solid topline while results were lower than exp...
The Q2 report confirmed that Absolent is on the right track with organic growth of 7% and margins im...
* Sales SEK 247m, 8% above ABGSCe on DRPS and FM&WT * Scandpower loss on licence timing and growth s...
* Net commission income miss * Negative TPV revisions result in lower earnings * Merchant base still...
* Q2e: Sales of SEK 1,159m & adj. EBIT of SEK 41m FX raises '26e-'28e adj.
Redeye provides a preview of its estimates ahead of Stille's Q2 results, scheduled for release on Ju...